|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM125955960 |
| 003 |
DE-627 |
| 005 |
20231222210832.0 |
| 007 |
tu |
| 008 |
231222s2003 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0420.xml
|
| 035 |
|
|
|a (DE-627)NLM125955960
|
| 035 |
|
|
|a (NLM)12833220
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Murphy, K F
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Fecal alpha1-proteinase inhibitor concentration in dogs with chronic gastrointestinal disease
|
| 264 |
|
1 |
|c 2003
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 09.09.2003
|
| 500 |
|
|
|a Date Revised 07.11.2019
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a BACKGROUND: Fecal alpha(1)-proteinase inhibitor (alpha(1)-PI) clearance is a reliable, noninvasive marker for protein-losing enteropathy in human beings. An assay for use in dogs has been developed and validated
|
| 520 |
|
|
|a OBJECTIVE: The aim of this study was to evaluate fecal alpha(1)-PI concentration in dogs with chronic gastrointestinal disease, compared with healthy dogs, and to assess its correlation with serum albumin concentration
|
| 520 |
|
|
|a METHODS: Fecal samples were collected from 2 groups of dogs. Group 1 consisted of 21 clinically healthy client-owned dogs without signs of gastrointestinal disease. Group 2 consisted of 16 dogs referred for investigation of suspected gastrointestinal disease. On the basis of gastric and duodenal biopsies, group 2 was further subdivided into dogs with normal histology (n = 9) and those with histologic abnormalities (n = 7: inflammatory bowel disease, n = 3; lymphangiectasia, n = 4). An ELISA was used to measure alpha(1)-PI concentrations in fecal extracts
|
| 520 |
|
|
|a RESULTS: Fecal alpha(1)-PI concentrations, expressed as micro g/g of feces, were not significantly different between groups 1 and 2 as a whole. However, fecal alpha(1)-PI concentrations (median, minimum-maximum) were significantly higher in dogs with gastrointestinal diseases associated with histologic abnormalities (60.6 micro g/g, 7.4-201.7 micro g/g) compared with dogs with normal histology (3.8 micro g/g, 0.7-74.0 micro g/g) and control dogs (9.9 micro g/g, 0.0-32.1 micro g/g). There was no significant correlation between fecal alpha(1)-PI and serum albumin concentrations in dogs with gastrointestinal disease
|
| 520 |
|
|
|a CONCLUSIONS: Increased fecal alpha(1)-PI concentration may signal the need to obtain gastrointestinal biopsies for a final diagnosis. Fecal alpha(1)-PI concentration may be a useful test for early detection of protein-losing enteropathy before decreases in serum albumin concentration can be detected
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Serine Proteinase Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Serum Albumin
|2 NLM
|
| 650 |
|
7 |
|a alpha 1-Antitrypsin
|2 NLM
|
| 700 |
1 |
|
|a German, A J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ruaux, C G
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Steiner, J M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Williams, D A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hall, E J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Veterinary clinical pathology
|d 1975
|g 32(2003), 2 vom: 03., Seite 67-72
|w (DE-627)NLM098159984
|x 1939-165X
|7 nnns
|
| 773 |
1 |
8 |
|g volume:32
|g year:2003
|g number:2
|g day:03
|g pages:67-72
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 32
|j 2003
|e 2
|b 03
|h 67-72
|